Pulmonary Fungal Disease: Diagnosis And Management Consensus
Pulmonary fungal disease spans aspergillosis, cryptococcosis, and candidiasis; a structured diagnosis and targeted antifungals are key to better outcomes.
Scope Of Disease
Pulmonary fungal disease includes several infections, with Aspergillus, Cryptococcus, and Candida as the main culprits. It chiefly threatens people with weak immunity, but occasionally affects apparently healthy hosts.
Graded Diagnosis
Experts favor three tiers: proven, probable, and possible. Proven requires tissue or sterile-fluid evidence. Probable adds host risk, clinical signs, and mycology. This helps standardize care while allowing clinical judgment.
Key Investigations
Chest CT, sputum and bronchoscopy fluid culture, and blood tests such as galactomannan, beta-D-glucan, and cryptococcal antigen guide diagnosis. Tissue biopsy remains definitive when doubt persists.
Treatment Principles
Voriconazole leads for invasive aspergillosis; fluconazole or amphotericin B with flucytosine treats cryptococcosis; candidiasis follows susceptibility. Courses often last weeks and end only after clinical and imaging improvement.
Prevention And Follow Up
High-risk patients may receive preventive antifungals. Reducing immune suppression and monitoring response are vital. Unnecessary or prolonged antifungal use should be avoided to limit toxicity and resistance.
